- Home
- KRYS vs TMHC Comparison
KRYS vs TMHC Comparison
Compare KRYS & TMHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRYS | TMHC |
|---|---|---|
| Founded | 2015 | 1936 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.2B |
| IPO Year | 2017 | 2013 |
Fundamental Metrics
Financial Performance| Metric | KRYS | TMHC |
|---|---|---|
| Price | $246.66 | $58.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $226.56 | $76.83 |
| AVG Volume (30 Days) | 289.5K | ★ 1.0M |
| Earning Date | 02-18-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 275.72 | 10.21 |
| EPS | 6.66 | ★ 8.31 |
| Revenue | $373,164,000.00 | ★ $8,378,329,000.00 |
| Revenue This Year | $36.14 | N/A |
| Revenue Next Year | $41.80 | N/A |
| P/E Ratio | $37.43 | ★ $7.11 |
| Revenue Growth | ★ 54.51 | 6.98 |
| 52 Week Low | $122.80 | $51.90 |
| 52 Week High | $265.92 | $72.50 |
Technical Indicators
Market Signals| Indicator | KRYS | TMHC |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 38.43 |
| Support Level | $235.61 | $57.24 |
| Resistance Level | $257.95 | $59.57 |
| Average True Range (ATR) | 7.62 | 1.28 |
| MACD | -1.55 | -0.16 |
| Stochastic Oscillator | 57.06 | 20.79 |
Price Performance
Historical ComparisonAbout KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.